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Edited by Beat ImhofAbstract Homophilic engagement of platelet endothelial cell
adhesion molecule-1 (PECAM-1/CD31) induces ‘outside-in’
signal transduction that results in phosphorylation events and
recruitment and activation of signalling molecules. The forma-
tion of signalling scaﬀolds with PECAM-1 are important
signalling events that modulate platelet secretion, aggregation
and platelet thrombus formation. In this study, we describe a
novel interaction between PECAM-1 and cytosolic calmodulin
(CaM) in platelets. Reciprocal co-immunoprecipitation studies
revealed that cytosolic CaM is constitutively associated with
PECAM-1 in resting, thrombin activated and aggregated human
platelets. Our studies demonstrate that CaM directly interacts
with a PECAM-1 peptide (594–604) C595A containing the
sequences 594KAFYLRKAKAK604. This CaM:PECAM-1 inter-
action has a threefold higher aﬃnity than CaM:GPVI interac-
tion. It is potentiated by the addition of calcium ions, and
dissociated by the CaM inhibitor, triﬂuoperazine. Treatment of
platelets with CaM inhibitors triggers cleavage of PECAM-1 in
a time- and dose-dependent manner. Furthermore, this mem-
brane proximal portion of PECAM-1 is conserved across
mammalian species and the helical representation of basic/
hydrophobic residues reveals a charge distribution analogous to
other CaM-binding motifs in other proteins. Taken together,
these results suggest that this highly charged cluster of amino
acids in the PECAM-1 cytoplasmic domain directly interacts
with CaM and this novel interaction appears to regulate cleavage
of PECAM-1.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Platelet endothelial cell adhesion molecule-1 (PECAM-1/
CD31) belongs to the immunoglobulin (Ig)-immunoreceptor
tyrosine-based inhibitory motif (ITIM) supergene family and is
known to mediate calcium-independent homophilic cell–cell
binding [1–5]. Other speciﬁc heterophilic ligands have been
proposed including integrin avb3 and ectoenzyme CD38 [6,7].
PECAM-1 contains six extracellular Ig-like domains, a trans-
membrane domain and a cytoplasmic domain. PECAM-1 is
expressed on the surface of myeloid cells, na€ıve B cells, na€ıve T
cells, natural killer cells, mast cells, platelets and endothelial
cells. Given its abundant expression, PECAM-1 has been
demonstrated to be involved in the initial formation and sta-
bilisation of cell–cell contacts at the lateral junctions of en-
dothelial cells, in the maintenance of vascular permeability,
modulation of transendothelial migration of monocytes and
neutrophils and formation of new blood vessels in angiogenesis
[8–14]. In the vasculature, it also serves as a virulence-associ-
ated endothelial receptor for binding Plasmodium falciparum-
infected erythrocytes [15].
Engagement of PECAM-1 induces ‘outside-in’ signalling
events that induce tyrosine phosphorylation of the PECAM-1
cytoplasmic domain with protein-tyrosine phosphatase (PTP)
recruitment and activation that results in selective dephos-
phorylation and ‘inside-out’ signalling that serves to disrupt
cell adhesion. The mechanisms of initiating and terminating
‘outside-in’ signalling through PECAM-1 are important new
avenues of investigation [16]. Examination of PECAM-1-de-
ﬁcient mice has revealed that PECAM-1 serves as a major
negative regulator of immunoreceptor tyrosine-based activa-
tory motif-associated signalling pathways, involving collagen
GPVI/FcR c-chain in platelets, B-cell receptor antigen com-
plex on B cells, and FcRI-mediated signalling on mast cells
[17–20]. PECAM-1 is active in transmembrane signalling
mediated by the direct recruitment and activation of speciﬁc
PTPs to phosphorylated ITIMs [1,4,21–24]. Apart from PTPs,
PECAM-1 associates with other cytoplasmic signalling and
cytoskeletal molecules including b-catenin, c-catenin, phos-
pholipase C (PLC)-c1, and phosphatidylinositol 3-kinase (PI
3-kinase) [25–28]. However, it remains unclear whether these
molecules directly interact with the PECAM-1 cytoplasmic
domain and how these interactions are regulated.ation of European Biochemical Societies.
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extracellular domain and a cluster of highly conserved charged
amino acid residues in the juxtamembrane region of PECAM-
1 was suﬃcient to confer eﬃcient localisation of the molecule
to cell–cell borders of PECAM-1-expressing cells [29]. We
hypothesized that these highly charged residues may be im-
portant in cytoskeletal reorganisation via the direct recruit-
ment of signalling molecules and/or cytoskeletal components.
One of the candidate molecules that was investigated was
calmodulin (CaM).
In this study, we demonstrate that cytosolic CaM, a calcium
sensory protein, is speciﬁcally co-precipitated with PECAM-1
from lysates of resting platelets, activated platelets and/or ag-
gregated platelets. We further show with synthetic peptides
based on the cytoplasmic domain of PECAM-1 that posi-
tionally located positively charged residues, 599RKAKAK604,
in the juxtamembrane region mediate the direct interaction of
PECAM-1 with cytosolic CaM derived from platelets or with
puriﬁed CaM. This CaM:PECAM-1 peptide interaction is
potentiated by the addition of calcium ions. This interaction of
PECAM-1 with cytosolic CaM appears to regulate intracel-
lular receptor cleavage, as CaM inhibitors induce cleavage of
PECAM-1 in platelets.2. Materials and methods
2.1. General reagents
Bovine serum albumin, prostaglandin E1, bovine CaM, phenyl-
methylsulfonyl ﬂuoride (PMSF), sodium orthovanadate, leupeptin,
streptavidin–agarose beads and human thrombin were purchased from
Sigma Chemical Company (St. Louis, MO). Prestained markers were
obtained from Invitrogen (Carlsbad, CA). Protein G–Sepharose beads
and cyanogen bromide (CNBr)-activated Sepharose beads were pur-
chased from Amersham Pharmacia Biotech AB (Uppsala, Sweden).
2.2. Antibodies
A rabbit polyclonal antibody against human PECAM-1 (SEW16)
and a mouse monoclonal antibody against domain 1 of human PE-
CAM-1 (PECAM-1.3) were a kind gift of Dr. Peter Newman (Blood
Research Institute, Milwaukee, WI). The polyclonal SEW41 anti-PE-
CAM-1 cytoplasmic domain antibody was generated by immunising
rabbits with puriﬁed recombinant PECAM-1 cytoplasmic domain
protein. The polyclonal SEW41 IgG antibody speciﬁcally recognised
the cytoplasmic domain of PECAM-1 when tested with transfected cell
lines expressing PECAM-1:ICAM-1 chimeras with only positive re-
activity in immunoprecipitates in the presence of the PECAM-1 cy-
toplasmic domain. This polyclonal anti-PECAM-1 antibody
recognises PECAM-1 in either a native or denatured form. A mouse
monoclonal antibody directed against human CD151 (11B1) was a
kind gift from Professor Leonie Ashman (University of Newcastle,
Newcastle, NSW). These antibodies have been previously character-
ised [1]. Mouse monoclonal anti-CaM IgG1 antibody was obtained
from Upstate Biotechnology (Lake Placid, NY). Normal mouse IgG1
antibody was obtained from Sigma.
2.3. Preparation of washed platelets
Human platelets were obtained from healthy volunteers that were
free of any anti-platelet drug medication for the preceding seven days.
Platelets were washed according to a previously described method [1].
2.4. Platelet activation/aggregometry studies
Washed platelets (1 108/ml) were either left unstimulated, or
stimulated with 1 U/ml thrombin (Sigma Chemical Company, St.
Louis, MO) for 5 min at 37 C without stirring. Platelet aggregation
was induced by 1 U/ml thrombin with stirring (1000 rpm) in the
presence of 1 mM CaCl2, 1 mMMgCl2 and 100 lg/ml ﬁbrinogen for 1
min at 37 C in a Payton dual-channel aggregation module (Paton
Scientiﬁc, Adelaide, Australia). Platelets were also pre-incubated with20 g/ml c7E3 Fab (Reopro) (Centocor B.V., Leiden, Netherlands) for
10 min at 37 C with stirring (1000 rpm) prior to activation with 1 U/
ml thrombin in the presence of 1 mM CaCl2, 1 mMMgCl2 and 100 lg/
ml ﬁbrinogen for 1 min at 37 C in the dual-channel aggregometer.
2.5. Preparation of platelet extracts
Platelets subjected to activation or aggregation were lysed by the
addition of 0.5 ml of Triton lysis buﬀer [15 mM HEPES, pH 7.4,
containing 1% (v/v) Triton X-100, 10 mM EGTA, 145 mM NaCl, 0.1
mM MgCl2, 1 mM PMSF, 20 lg/ml leupeptin, and 2 mM sodium
orthovanadate], and the lysate constantly mixed for 1 h at 4 C. Tri-
ton-soluble platelet fractions were isolated by centrifugation at
15 000 g, 4 C for 15 min.
2.6. Immunoprecipitation and Western blot studies of platelet lysates
Following fractionation of Triton-soluble platelet supernatant, ly-
sates were precleared with 50 ll of a 50% slurry of CNBr-activated
Sepharose beads (Amersham Pharmacia Biotech AB, Uppsala, Swe-
den) for 15 min at 4 C with constant mixing and centrifuged at 4000
rpm for 5 min. Immunoprecipitation (IP) studies from Triton-soluble
precleared platelet fractions were performed with 10 lg of normal
mouse IgG1, PECAM-1.3 IgG or anti-CaM IgG1 for 2 h at 4 C with
constant mixing. A 50% slurry (50 ll) of Protein G–Sepharose beads
(Amersham Pharmacia Biotech AB, Uppsula, Sweden) was added and
incubated for a further hour at 4 C with constant mixing. The beads
were then washed ﬁve times with IP buﬀer [50 mM Tris, pH 7.4,
containing 150 mM NaCl and 1% (v/v) Triton X-100] and centrifuged
at 4000 rpm for 5 min. Bound proteins were eluted from the beads by
addition of 30 ll SDS reducing buﬀer and samples were boiled for 10
min. Eluted proteins were resolved on either a 10% or 12.5% SDS–
PAGE. For Western blot studies, proteins were transferred to poly-
vinylidene diﬂuoride (PVDF) membrane by semidry Western blotting.
Membranes were blocked by a 1 h incubation at room temperature
with blocking buﬀer [20 mM Tris, pH 7.4, containing 3% (wt/v) bovine
serum albumin and 0.05% (v/v) Tween 20] and immunoblotted with
anti-human PECAM-1 (SEW16) (10 lg/ml) and anti-CaM (1:2000).
Blots were visualised using the appropriate horseradish peroxidase-
coupled anti-rabbit or anti-mouse secondary antibody (1:10 000) (Si-
lenus, Hawthorn, Australia). Following washing with Tris-buﬀered
saline [TBS; 20 mM Tris, pH 7.4, containing 150 mM NaCl and 0.05%
(v/v) Tween 20], blots were developed with enhanced chemilumines-
cence detection system according to the manufacturer’s instructions
(Amersham, Buckinghamshire, UK).
2.7. Surface plasmon resonance studies
Streptavidin-coated BIAcore sensor chips SA (BIAcore AB, Upp-
sala, Sweden) were conditioned with 1 M NaCl in 50 mM NaOH ac-
cording to the manufacturer’s instructions. All experiments were
carried out in HBS buﬀer (0.01 M HEPES, pH 7.4, containing 0.15 M
NaCl, 3 mM EDTA, and 0.005% (v/v) superfactant) with a ﬂow rate of
5 ll/min and a constant temperature of 25 C. For each series of ex-
periments, 30 ll of biotinylated PECAM-1-(594–604) peptide or bio-
tinylated GPVI (294–309) peptide (100 lg/ml) was injected into the
respective chip. The sensor surface was regenerated with 0.1 M HCl
following each protein run. For determination of aﬃnity constants for
the interaction of bovine CaM with PECAM-1 or GPVI peptides, 30 ll
of diﬀerent concentrations of bovine CaM (131–2630 nM) was injected
into the sensor chip. Equilibrium-binding isotherms were evaluated in
the BIAcore evaluation program. Data were analysed by linear re-
gression analysis using Graph Pad Prism Version 2.0.
2.8. Calmodulin ELISA
Microtiter plates (Nunc Maxisorb, MEDOS) were coated overnight
at 4 C with 50 ll of bovine CaM diluted in 0.05 M carbonate buﬀer,
pH 9.6, at 10 lg/ml and blocked with 2% (wt/v) bovine serum albumin
diluted in PBS for 1 h at 37 C. Plates were washed with PBS con-
taining 0.05% (v/v) Tween 20 (PBS/Tween), and a dose–response (0–20
lg/ml) of respective biotinylated PECAM-1 peptides (wild-type PE-
CAM-1 594–604, RK!AA and KAK!AAA mutated or scrambled
forms of PECAM-1 594–604 peptide) diluted with PBS/Tween and
incubated for 2 h at room temperature. The plates were then washed
and incubated for 1 h with streptavidin–alkaline phosphatase diluted
1:1000 in PBS/Tween. After additional washings, 50 ll of p-nitrophe-
nyl phosphate substrate (Sigma) diluted in diethanolamine buﬀer at 1
mg/ml was applied. Absorbances were read after 20 min at 405 nm. To
Fig. 1. Interaction of cytosolic CaM with full-length platelet PECAM-
1. Platelets (1 109/ml) were incubated at 37 C and stimulated with
the following agonists in the presence of 1 mM CaCl2, 1 mM MgCl2,
and 100 lg/ml ﬁbrinogen: (1) Buﬀer (stirred); (2) 1 U/ml thrombin for 5
min without stirring; (3) 1 U/ml thrombin for 5 min (stirred and ag-
gregated); and (4) 1 U/ml thrombin (stirred) in the presence of 20 lg/ml
c7E3 Fab (Reopro). Washed platelets were pre-incubated with 20 lg/
ml c7E3 Fab (Reopro) for 10 min before thrombin stimulation for 5
min at 37 C with stirring. Following detergent lysis, IPs were per-
formed using either normal mouse IgG1 (left top and bottom panels),
PECAM-1.3 IgG1 (right bottom panel) or CaM IgG1 (right top panel).
Bound proteins were resolved on 12.5% SDS–PAGE and analysed by
immunoblotting using polyclonal anti-PECAM-1 (SEW16) (top pa-
nel), anti-CaM (second and third panel) or anti-CD151 (bottom pa-
nel). The migration and speciﬁcity of either CaM or PECAM-1 is
conﬁrmed by subjecting 5 lg platelet lysate to the immunoblot anal-
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parallel assays included a ﬁnal concentration of 5–1200 lM triﬂuo-
perazine (Calbiochem, Richmond, CA).
2.9. Peptide synthesis
Biotinylated synthetic peptidesTyr(PO4) based on cytoplasmic
domain sequences of human PECAM-1 were synthesised and prior to
cleavage the resin was coupled with 1.5-fold molar excess of NHS-long
chain (LC) biotin (Pierce, Rockford, IL) at the N-terminus and puri-
ﬁed by reverse-phase high-pressure liquid chromatography (HPLC) to
>90% purity. All peptides were characterised by ion spray mass
spectroscopy to conﬁrm the expected molecular-mass for both the non-
phosphorylated and phosphorylated PECAM-1 cytoplasmic domain
peptides. These biotinylated 25-mer and 11-mer peptides were gener-
ated by Chiron Mimotopes (Clayton, Vic., Australia). The scrambled
PECAM-1 594–604 peptide sequence was KYKARFKLAKA, while
RK!AA PECAM-1 594–604 peptide sequence was KAY-
FLAAAKAK and KAK!AAA PECAM-1 594–604 peptide se-
quence was KAYFLRKAAAA. All lyophilised biotinylated peptides
were prepared as 1 mg/ml solutions and dissolved in 10 mM sodium
phosphate and 150 mM NaCl, pH 7.4, containing 0.3% (v/v) dimethyl
sulfoxide (DMSO) and stored at 4 C.
2.10. Peptido-precipitation studies using platelet lysates
Biotinylated synthetic peptides (10 lg/ml) were incubated with 1 ml
of 15 000 g Triton-solubilised platelet lysates and incubated over-
night at 4 C with constant mixing. 50 ll of a 50% suspension of
streptavidin–agarose beads (Sigma) was added to all tubes and the
peptide mixture incubated for a further hour at 4 C with constant
mixing. The beads were then washed ﬁve times with IP buﬀer [50 mM
Tris, pH 7.4, containing 150 mMNaCl and 1% (v/v) Triton X-100] and
centrifuged at 4000 rpm for 5 min. Bound proteins were eluted from
the beads by addition of 30 ll SDS reducing buﬀer and samples were
boiled for 10 min. Eluted proteins were resolved on 10% or 12.5%
SDS–PAGE.
2.11. Peptido-precipitation studies using puriﬁed bovine calmodulin
Biotinylated synthetic PECAM-1 peptides (10 lg/ml) were incubated
with 1 lg of puriﬁed bovine CaM dissolved in 1 ml PBS for 1 h at 4 C
with constant mixing. A 50% suspension of streptavidin–agarose beads
(50 ll) was added to all tubes and incubated for a further hour at 4 C
with constant mixing. The beads were washed three times with a
modiﬁed IP buﬀer (50 mM Tris, pH 7.4, containing 150 mM NaCl)
and processed as described for immunoprecipitates.ysis. Stds, standards. Results are representatives of three separate
experiments.3. Results
3.1. Constitutive association of calmodulin with PECAM-1
from platelet lysates
Examination of PECAM-1 cytoplasmic domain sequences
revealed the presence of a cluster of positively charged amino
acids in the juxtamembrane region analogous to CaM-binding
sequences in other transmembrane receptors. In order to
determine if CaM might be involved in binding to the cyto-
plasmic domain of PECAM-1, we performed reciprocal co-
immunoprecipitation studies of Triton-soluble platelet lysates.
In these experiments, PECAM-1 or CaM was immunopre-
cipitated from lysates of platelets that had been pretreated with
iodoacetamide followed by (a) treatment with buﬀer (resting),
(b) thrombin activated but not aggregated, (c) thrombin acti-
vated and fully aggregated and (d) treatment with integrin
aIIbb3 and avb3 blocker, c7E3 Fab (Reopro) prior to thrombin
activation and stirring of platelets. Normal mouse IgG1 was
used as an isotype-matched control. Following IP, the presence
of PECAM-1 and/or CaM in reciprocal precipitates was de-
tected by immunoblot analysis. As shown in Fig. 1, PECAM-1
was constitutively associated with CaM under resting condi-
tions and following platelet activation and aggregation (topand second panels). In contrast, CaM was not co-precipitated
with the tetraspanin superfamily member, CD151, from resting
and activated platelet lysates (Fig. 1, third and bottom panels).
Together, these data provide strong evidence that the associ-
ation of CaM with PECAM-1 occurs in vivo in primary cells
such as platelets. This PECAM-1:CaM interaction was not
only found in platelets but is also active in other cell types
including T cells that express PECAM-1 (data not shown).
3.2. Direct binding of calmodulin to the cytoplasmic domain of
PECAM-1
To address whether CaM binds directly to the cytoplasmic
domain of PECAM-1, we synthesised a series of overlapping
biotinylated 25-mer peptides corresponding to the entire cy-
toplasmic domain of human PECAM-1; the C-terminal pep-
tides 684–711, is a 29-mer (Fig. 2A). These biotinylated
peptides were mixed with puriﬁed bovine CaM and bound
protein recovered using streptavidin–agarose beads. Immu-
noblot analysis using an anti-CaM monoclonal antibody
demonstrated that CaM bound only to the PECAM-1-(594–
619) C595A peptide (Fig. 2B). Using this assay, it appears that
CaM is binding to a region encompassing PECAM-1-(594–
Fig. 2. Association of puriﬁed bovine CaM with overlapping PECAM-
1 cytoplasmic domain peptides. A. Design of overlapping biotinylated
PECAM-1 cytoplasmic domain peptides used in this study. The ma-
jority of the peptides were 25-mer in length. The only exception was
PECAM-1683–711, which was a 29-mer peptide. B. CaM immunoblot of
proteins captured by PECAM-1 cytoplasmic domain peptides. 1 lg of
puriﬁed bovine CaM was incubated with 10 lg of each biotinylated
PECAM-1 cytoplasmic domain peptide suspended in PBS. Protein–
peptide complexes were captured using streptavidin–agarose beads,
separated by SDS–PAGE transferred to a polyvinylidene diﬂuoride
(PVDF) membrane, and subjected to immunoblot analysis using a
monoclonal antibody directed to CaM. Note that PECAM-1-(594–
619) C595A peptide (lane 2) bound CaM. The migration of CaM was
also demonstrated by the loading of 0.5 lg puriﬁed bovine CaM (lane
9). Stds, standards.
Fig. 3. Association of CaM with PECAM-1 cytoplasmic domain
peptides. A. Design of biotinylated PECAM-1 cytoplasmic domain
peptides used in this study. An identical set of biotinylated PECAM-1
cytoplasmic domain phosphopeptides (not shown) was prepared using
a phosphorylated tyrosine amino acid in the appropriate position. B.
CaM immunoblot of proteins captured by PECAM-1 cytoplasmic
domain peptides. Protein (1.5 mg) derived from the 15 000 g super-
natant of Triton-solubilised resting platelets was incubated with each
biotinylated PECAM-1 cytoplasmic domain peptide. Protein–peptide
complexes were captured using streptavidin–agarose beads, separated
by SDS–PAGE, transferred to PVDF membrane, and subjected to
immunoblot analysis using a CaM antibody. Note that PECAM-1-
(594–604) C595A and PECAM-1-(594–604) C595A 596 Y(P) peptides
(lanes 2 and 3) bound to CaM, indicating that tyrosine phosphoryla-
tion of Y596 was not required for the interaction. The migration of
CaM and speciﬁcity of the immunoblot was demonstrated by sub-
jecting 5 lg of platelet lysate to CaM immunoblot analysis (lane 12). C.
CaM immunoblot of proteins captured by PECAM-1 cytoplasmic
domain and GPVI peptides. 1 lg of puriﬁed bovine CaM was incu-
bated with 10 lg of each biotinylated PECAM-1 cytoplasmic domain
peptide suspended in PBS. Protein–peptide complexes were captured
using streptavidin–agarose beads, separated by SDS–PAGE, trans-
ferred to a PVDF membrane, and subjected to immunoblot analysis
using a monoclonal antibody directed to CaM. Note that PECAM-1-
(594–604) C595A and PECAM-1-(594–604) C595A 596 Y(P) peptides
(lanes 2 and 3) bound to CaM. The migration of CaM was also
demonstrated by the loading of 0.5 lg puriﬁed bovine CaM (lane 12).
Stds, standards, Y(P), phosphotyrosine.
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to bind CaM.
In order to narrow down the sequences required for CaM
binding to PECAM-1, we synthesised a matched series of
biotinylated 11-amino acid peptides corresponding to a speciﬁc
region of the PECAM-1 cytoplasmic domain with and without
phosphorylation of respective tyrosine residues (Fig. 3A).
These biotinylated peptides were mixed with detergent lysates
of resting human platelets and bound proteins were recovered
with streptavidin–agarose beads. Immunoblot analysis using a
speciﬁc CaM antibody revealed that CaM bound to PECAM-
1-(594–604) C595A and PECAM-1-(594–604) C595A Y(P)596
peptides (Fig. 3B). These results indicate that the cysteine
residue at position 595 and tyrosine residue at position 596 are
not required for binding CaM with PECAM-1. In addition,
the likely sequences involved in CaM binding to PECAM-1
involve residues 594–604.
In order to conﬁrm whether this direct interaction involves a
distinct CaM-binding motif between CaM and PECAM-1, we
used these biotinylated 11-mer peptides in an in vitro assay. As
shown in Fig. 3C, puriﬁed bovine CaM associated only with
PECAM-1-(594–604) C595A, PECAM-1-(594–604) C595A
Y(P)596 and GPVI peptides. In order to exclude the possibility
that the interaction was mediated solely based on charged
amino acids, we examined PECAM-1-(594–604) mutant
RK!AA, KAK!AAA and a scrambled version of the
peptide in a CaM-based ELISA assay. As shown in Fig. 4A,
only the wild-type (594–604) PECAM-1 peptide showed
binding to puriﬁed bovine CaM, while an RK!AA mutant,
KAK!AAA mutant and a scrambled version of the PE-CAM-1 peptide failed to bind to bovine CaM. This interaction
between CaM and wild-type (594–604) PECAM-1 peptide
could be displaced by titration with a CaM inhibitor, triﬂuo-
perazine (Fig. 4B). These CaM inhibitors function by blocking
the interaction of CaM with its substrates [30]. This
CaM:PECAM-1 peptide interaction was also potentiated by
the addition of calcium ions (Fig. 4C). In addition, in peptide-
precipitation studies we have also conﬁrmed that the wild-type
(594–604) PECAM-1 peptide and GPVI peptide showed
binding to puriﬁed bovine CaM, while a negative control
Fig. 4. CaM binds directly to a cytoplasmic-binding motif in PECAM-1. A. Puriﬁed bovine CaM was absorbed to the bottom of microtiter wells.
Biotinylated 11-mer PECAM-1 peptides (594–604) either as wild-type, RK!AA, KAK!AAA and scrambled versions were titrated at various
concentrations, as indicated. Binding of each peptide was visualised by the addition of streptavidin-alkaline phosphatase and p-nitrophenyl phos-
phate substrate. B. The binding of CaM to the PECAM-1 cytoplasmic domain peptide (594–604) is inhibited by triﬂuoperazine. The biotinylated
PECAM-1-(594–604) peptide was incubated with immobilised CaM in the presence and absence of triﬂuoperazine and titrated at various concen-
trations, as indicated. C. Diﬀerent molar ratios of biotinylated PECAM-1 594–604 peptide (0–20) with puriﬁed bovine CaM were incubated in the
presence of 1 mM CaCl2 or 10 mM EGTA. Protein–peptide complexes were captured using streptavidin–agarose beads, separated by SDS–PAGE,
transferred to PVDF membrane, and subjected to CaM immunoblot analysis. The migration of CaM was also demonstrated by the loading of 0.5 lg
puriﬁed bovine CaM (lane 13). Stds, standards. D. CaM immunoblot of proteins captured by PECAM-1 cytoplasmic domain mutant peptides and
GPVI peptide. 1 lg of puriﬁed bovine CaM was incubated with 10 lg of each biotinylated PECAM-1 cytoplasmic domain peptide or GPVI peptide
suspended in PBS. Protein–peptide complexes were processed as described in the legend for Fig. 3C.
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KAK!AAA mutant and a scrambled version of the PE-
CAM-1 peptide failed to bind to bovine CaM (Fig. 4D). To-
gether, these data indicate that the PECAM-1 cytoplasmic
domain can directly bind CaM that requires a distinct CaM-
binding motif in the PECAM-1 cytoplasmic domain.
3.3. Calmodulin inhibitors induce cleavage of PECAM-1 in
platelets
Previous studies have shown that CaM inhibitors can induce
cleavage of several membrane proteins, including L-selectin,
the membrane-bound growth factor precursors pro-trans-
forming growth factor-a, the receptor tyrosine kinase, TrkAand the b-amyloid precursor protein [30]. To investigate
whether an analogous mechanism regulates the cleavage of
PECAM-1 on the surface of platelets, we ﬁrst analysed the
eﬀects of CaM inhibitors on the cleavage of PECAM-1. In
these experiments, resting platelets were stimulated with dif-
ferent CaM inhibitors, W7 and triﬂuoperazine (TFP) either as
a dose–response or time course, then platelets were lysed,
electrophoresed and blotted for PECAM-1 antigen. As shown
in Fig. 5A–C, the CaM inhibitors, W7 and TFP induced a
rapid cleavage of PECAM-1 from a 120 kDa form to a 100
kDa form in both a time- and dose-dependent manner. This
100 kDa form of PECAM-1 lacks its cytoplasmic domain as
demonstrated by loss of reactivity with a polyclonal anti-PE-
Fig. 5. CaM inhibitors trigger the cleavage of PECAM-1 in platelets.
A. Washed human platelets (1 109/l) were treated with CaM inhibi-
tor, W7 (20 lM), for a time course (0–15 min) or over a dose-depen-
dent range 0–100 lM W7 for 30 min at 37 C. W7-treated platelets
were lysed with Triton-lysis buﬀer and 200 lg of lysates was subjected
to SDS–PAGE and Western blotting with polyclonal anti-PECAM-1
antibody (SEW32). B. Washed human platelets (1 109/l) were treated
with CaM inhibitor, TFP (100 lM), for a time course of 0–40 min or
over a dose-dependent range 0–200 lM TFP for 30 min at 37 C. TFP-
treated platelets were lysed with Triton X-100 lysis buﬀer and 200 lg of
lysates was subjected to SDS–PAGE and Western blotting with
polyclonal anti-PECAM-1 antibody (SEW32). C. Same experimental
conditions as A, except the Western blot was probed with a polyclonal
anti-PECAM-1 cytoplasmic domain antibody (SEW41). D. Washed
human platelets (1 109/l) were treated with CaM inhibitor, TFP (100
lM), for a time course (0–40 min) or over a dose-dependent range 0–
200 lMTFP for 30 min at 37 C. TFP-treated platelets were lysed with
Triton-lysis buﬀer and 200 lg of lysates was subjected to SDS–PAGE
and Western blotting with monoclonal anti-CD151 antibody (11B1).
E. Triﬂuoperazine does not induce PECAM-1 shedding from the
surface of human platelets. 1 ml aliquots of washed human platelets
(1 109 platelets/ml) were treated with 200 lM TFP at 37 C over
time. PECAM-1 and CD151 expressions on the surface of platelets
were monitored over time by ﬂow cytometry. Data are represented
as meansS.E.M. and are representatives of at least three similar
experiments.
Fig. 6. Evolutionary conservation of the CaM-binding motif in PE-
CAM-1. A. The region of the cytoplasmic domain of PECAM-1 cor-
responding to amino acids 594–604. Positively charged amino acid
residues of human PECAM-1 involved in CaM binding and conserved
in other species are boxed. B. Cytoplasmic domain sequence of human
PECAM-1 showing sequences that interact with CaM.
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used relatively high concentrations of CaM inhibitors to in-
duce PECAM-1 cleavage, we wanted to exclude the possibilityof non-speciﬁc degradation of platelet membrane glycopro-
teins. Using similar conditions, we were able to show that
another platelet membrane glycoprotein, CD151, remains in-
tact in platelets exposed to high concentrations of CaM in-
hibitors (Fig. 5D). In order to exclude the possibility that
cleavage of PECAM-1 leads to receptor shedding from the
surface of platelets, we labelled human platelets with FITC-
conjugated anti-human PECAM-1 mAbs and then performed
a time course (0–4 h) of 400 lM TFP treatment. Treated
platelets were then washed and analysed by ﬂow cytometry to
monitor PECAM-1 expression over time. Over this time
course, we did not observe PECAM-1 receptor shedding from
the surface of platelets indicating the possibility that the 100
kDa form is still attached to the platelet membrane and that
displacement of CaM:PECAM-1 interaction exposes an in-
tracellular cleavage site (Fig. 5E).
3.4. Calmodulin-binding motif in PECAM-1
CaM-binding domains are characteristically amphipathic
helices that are rich in basic residues. The PECAM-1 cyto-
plasmic domain has a cluster of highly charged basic residues,
599RKAKAK604 (basic residues are shown in boldface) of which
these six amino acid residues are completely conserved across
species including human, murine, rat, bovine, porcine and
canine (Fig. 6A). The CaM-binding sequence in the cytoplas-
mic domain of PECAM-1 in the juxtamembrane region
(Fig. 6B) is analogous to CaM-binding sites in other receptors
including L-selectin, GPIbb and GPVI (Fig. 7A). A helical
model of the PECAM-1 cytoplasmic juxtamembrane region
shows a basic face similar to those seen in other CaM-binding
proteins including L-selectin, GPIbb and GPVI receptors
(Fig. 7B-C). CBCP (CaM-binding control peptide) is a non-
physiological control peptide, which forms an amphipathic
helix typical of CaM recognition sequences in other proteins
[31].
Predictive algorithms for identifying putative CaM recruit-
ment sites are now available to subclassify CaM-binding
domains in receptors and proteins [32,33]. When PECAM-1
594–604 sequence was submitted into these computer
Table 1
Equilibrium dissociation constants for the binding of bovine CaM with
human PECAM-1 and GPVI peptides
Immobilised
biotinylated peptide
Binding
protein
KD values (nM)
(Mean S.D.)
PECAM-1-(594–604)
(594KAYFLRKAKAK604)
Bovine CaM 39.93 13.63
GPVI-(294-309)
(294RRKRLRHRGRAVQRPL309)
Bovine CaM 154.80 63.78
KD values were obtained from linear regression analysis of equilibrium
sensorgrams over a 131–2630 nM concentration range of puriﬁed
bovine CaM, where saturable binding was observed by surface plas-
mon resonance analysis. Req values were derived at the point where
equilibrium had occurred after binding of bovine CaM. The
meanS.D. was derived from three independent experiments.
Fig. 7. Sequences within PECAM-1 compared to other CaM-recog-
nition sequences. A. Alignment of the CaM-binding cytoplasmic
sequence of PECAM-1 (Arg599–Ala614) with sequences spanning CaM-
binding sites in L-selectin (Arg356–Tyr372), GPIbb (Arg149–Arg164), and
GPVI (Arg294–Pro309). Identical residues or conserved substitutions
are highlighted. Positively charged lysine and arginine amino acids are
in bold. CBCP (CaM-binding control peptide) is a non-physiological
control peptide which forms an amphipathic helix typical of CaM
recognition sequences in other proteins [31]. B and C. Helical wheel
representation of the PECAM-1 sequence (Arg599–Met610) compared
with other CaM-binding protein sequences, GPIbb (Arg149–Leu167)
and GPVI (Arg294–Pro309).
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domain indicating that this is a novel CaM-binding sequence.
In order to test diﬀerences in aﬃnity for the PECAM-1 CaM-
binding domain with GPVI CaM-binding domain [basic 1-8-
(14)], surface plasmon resonance studies were carried out to
compare the capacity of PECAM-1 CaM-binding peptide
versus GPVI CaM-binding domain with puriﬁed bovine CaM.
As shown in Table 1, PECAM-1 594–604 sequence showed a
threefold higher aﬃnity than GPVI 294–309 sequence for
binding puriﬁed bovine CaM (40 versus 150 nM). Therefore,
based upon these results, PECAM-1 594–604 sequence would
appear to represent a new high-aﬃnity CaM-binding domain.4. Discussion
In this study, we provide several lines of evidence to dem-
onstrate a novel direct interaction between basic/hydrophobic
residues in the juxtamembrane region of PECAM-1 with cy-
tosolic CaM in platelets. First, CaM co-immunoprecipitated
with PECAM-1 from the Triton-soluble fraction of resting
platelets, thrombin-stimulated platelets and aggregated plate-
lets (Fig. 1). Second, peptido-precipitation studies revealed
that CaM-binding sites are localised to the juxtamembrane
region of PECAM-1 involving a highly charged cluster of
basic/hydrophobic amino acids, 599RKAKAK604 (Figs. 2 and
3). The PECAM-1 cytoplasmic domain peptides bound CaM
from platelet cytosol and this interaction is potentiated by the
presence of calcium ions. This interaction could be ablated by
mutation of 599RK600 to AA, 602KAK604 to AAA, or scram-
bling the CaM-binding motif in PECAM-1 and by displace-
ment using a CaM inhibitor, triﬂuoperazine (Figs. 4A–D). In
contrast, the intact PECAM-1 protein was co-immunoprecip-
itated with CaM from platelet extracts that contained EGTA
(Figs. 1 and 4C). This ﬁnding is consistent with previous re-
ports for other CaM-binding peptides such as those derived
from glycoprotein GPVI [34]. Treatment of platelets with CaM
inhibitors, W7 and TFP-induced cleavage of PECAM-1 but
not CD151 in a time- and dose-dependent manner (Fig. 5),
indicating that displacement of CaM from the PECAM-1 cy-
toplasmic domain may expose a cleavage site to allow prote-
olysis to occur.
The membrane proximal region of PECAM-1 contains a
12-amino acid sequence that is similar to other reported CaM-
binding sequences, including L-selectin, glycoprotein GPIbb,
GPV and GPVI [34]. These CaM-binding sequences comprise
a basic/hydrophobic composition that has the capacity to form
an amphipathic a-helix, that is typically observed in CaM
recognition sites (Fig. 7A–C). In PECAM-1, the sequence 599–
614 contains a proline residue at position 607 which would not
normally favour a-helix formation, although the structure of
this region of PECAM-1 has not been determined. A feature
observed in these transmembrane receptors with GPIbb is that
the CaM recognition sequence is ﬂanked at the N-terminus by
a palmitoylation site and at the C-terminus by a serine residue
that is phosphorylated by either protein kinase A (PKA) or
protein kinase C (PKC). PECAM-1 contains an unpaired
cysteine residue at position 595 that constitutes a potential site
for palmitoylation. It also contains a serine residue at amino
acid position 611 that is a potential site for phosphorylation by
either PKA or PKC. Further studies will be required to more
deﬁnitively deﬁne these sites in PECAM-1. A common mech-
anism of negatively regulating CaM binding is the induction of
serine phosphorylation at sites in or adjacent to the CaM-
binding site. There is now accumulating evidence that Ca2þ–
CaM and PKCs obstruct each others actions by the embedding
of PKC phosphorylation sites in CaM crypts or Ca2þ–CaM-
binding domains of its substrates [35]. These substrates have
been shown to contain critical serine residues which upon
phosphorylation by phorbol esters or with chemoattractants
disrupt CaM binding. These include L-selectin, GPIbb,
MARCKS, neuromodulin and neurogranin [36–41]. Studies in
resting human neutrophils have demonstrated that the con-
stitutive association of CaM with the cytoplasmic domain of
L-selectin is important for the topography of the extracellular
membrane cleavage domain of L-selectin, that normally ren-
M.-X. Wong et al. / FEBS Letters 568 (2004) 70–78 77ders it resistant to cleavage. L-selectin shedding can be induced
by stimulation by phorbol ester, PMA or CaM inhibitors that
release CaM from the L-selectin cytoplasmic domain and alter
the topography of the cleavage domain to allow proteolytic
cleavage to occur.
There is growing evidence that the ectodomains of a
number of transmembrane proteins can be shed by proteo-
lytic cleavage through the action of cell surface proteases.
Substrates include growth factor receptors, cell adhesion
molecules and extracellular matrix proteins [42–46]. Recent
studies examining the shedding of an adhesion molecule,
L-selectin, have shown that it is regulated by the interaction
of CaM with the cytoplasmic domain of L-selectin. Preven-
tion of the CaM:L-selectin interaction by CaM inhibitors or
mutation of the CaM-binding site on L-selectin induced
L-selectin ectodomain shedding [47]. Recent studies have re-
ported that CaM inhibitors trigger shedding of transmem-
brane proteins by a novel PKC- and Ca2þ-independent
mechanism [30]. These studies have indicated that there are
diﬀerent mechanisms for regulated receptor shedding induced
by CaM inhibitors, that is independent of CaM:substrate
recognition. Further studies will be required to resolve these
issues. PECAM-1 receptor shedding has been observed in
several clinical settings in vivo. For example, induction of
apoptosis results in endothelial cell shedding of the PECAM-
1 ectodomain from their surface [48]. PECAM-1 shedding
from the neutrophil surface has been reported in viral in-
fections such as respiratory syncytial virus in vivo [49].
Neutrophils may also shed PECAM-1 before or during ex-
travasation into inﬂamed tissues, as workers have observed
that the expression of neutrophil PECAM-1 is downregulated
after transendothelial migration into inﬂamed tissues [50].
However, in contrast to L-selectin, we did not observe
PECAM-1 ectodomain shedding following prevention of
CaM:PECAM-1 interaction in platelets. An exciting novel
ﬁnding in this study is the feature of intracellular cleavage of
PECAM-1 as a result of displacement of the CaM:PECAM-1
interaction by CaM inhibitors. This cleavage of PECAM-1
appears to produce a cytoplasmic domainless form of
PECAM-1. As the cleavage site is only exposed upon dis-
placement of the CaM:PECAM-1 interaction, it will be in-
teresting to examine physiological conditions where this
protein:protein interaction is disrupted.
Ca2þ–CaM provides a ubiquitous cellular sensor that acts as
a co-factor for regulating many enzymes involved in numerous
signalling pathways and plays a role in intracellular membrane
transport. These include Ral GTPases, RalA and RalB, acti-
vating the function of kinases (CaM kinase I and II, myosin
light chain kinase), phosphatases (calcineurin), transcription
factors, motor proteins, ion channels (plasma membrane Ca2þ
pump), metabolic enzymes and cytoskeletal components (my-
osin). Ca2þ–CaM has been shown to play a critical role in
calcium-dependent exocytosis [51]. CaM also acts as an ion
channel subunit for a variety of ion channels, including volt-
age-gated Ca2þ channels, non-selective cation channels, Ca2þ
or ligand-gated channels, Trp family channels and Ca2þ-
induced Ca2þ release channels from organelles [52]. Recent
reports indicate that PECAM-1 regulates a hydrogen perox-
ide-activated non-selective cation channel in endothelial cells
[53]. However, these workers reported that an intact ITIM in
PECAM-1 was important for conferring cation activity.
Therefore, further studies will be required to resolve thefunctional importance of the Ca2þ–CaM:PECAM-1 interac-
tion in regulating voltage-gated channel activity.
The basic/hydrophobic amino acids involved in CaM bind-
ing in the juxtamembrane region of PECAM-1 have been
shown to be suﬃcient to direct eﬃcient localisation of the
PECAM-1 molecule to cell–cell borders [29]. This feature
suggests that the PECAM-1:CaM interaction may be impor-
tant in linking this receptor with cytoskeletal components. This
hypothesis is further supported by the observation that cyto-
kine stimulation by either IFN-c or TNF-a leads to redistri-
bution of PECAM-1 away from cell–cell borders [54]. Studies
using temperature-sensitive CaM mutations in yeast Saccha-
romyces cerevisiae have demonstrated that CaM is an essential
protein for organisation of the actin cytoskeleton, endocytosis,
nuclear division and bud emergence [55]. CaM positively reg-
ulates phosphatidylinositol (4,5)-bisphosphate synthesis in S.
cerevisiae, which in turn regulates the interactions between
actin and the actin-binding proteins [55]. Rearrangement of the
actin cytoskeleton is an essential component that contributes
to cell motility and cell shape change that occurs during acti-
vation of platelets or neutrophils.
Previous studies have conﬁrmed that another Ig-ITIM su-
perfamily member, CEACAM-1 and CEACAM2, has the ca-
pacity to bind CaM involving basic/hydrophobic amino acids
in the juxtamembrane region of these molecules [56]. Using
dot-blot binding experiments, these workers showed that the
binding of CaM to the membrane proximal region of CEA-
CAM caused downregulation of homophilic self-self associa-
tion of CEACAM. These studies suggested that the
CaM:CEACAM interaction was suﬃcient to induce inside-out
signalling events that modulated the homophilic adhesive
properties of CEACAM [56].
In summary, this study has identiﬁed a direct physical
interaction between CaM and PECAM-1 that is detectable in
the presence and absence of detergent solubilised platelet
membranes and the speciﬁc recognition sequences in PECAM-
1 required for binding. In addition, release of CaM from the
PECAM-1 cytoplasmic domain by CaM inhibitors was asso-
ciated with exposure of a cleavage domain that allowed pro-
teolytic cleavage to occur. It will be of future interest to further
deﬁne other mechanisms that regulate PECAM-1 receptor
cleavage.Acknowledgements: We thank Dr. Peter Newman for supply of PE-
CAM-1.3 IgG monoclonal antibody and polyclonal anti-PECAM-1
SEW16 and SEW32 antibodies.References
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